Vol. 45 (3): 424-427, May – June, 2019
doi: 10.1590/S1677-5538.IBJU.2019.03.02
DIFFERENCE OF OPINION
Leonardo O. Reis 1, 2, Rodrigo Montenegro 3, Quoc-Dien Trinh 3
1 UroScience, Pontificia Universidade de Campinas – PUC, Campinas, SP, Brasil; 2 Departamento de Urologia, Universidade Estadual de Campinas – UNICAMP, Campinas, SP, Brasil; 3 Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Keywords: Prostatic Neoplasms; Prostatectomy; Radiotherapy
INTRODUCTION
Prostate cancer is the commonest non-skin malignancy in men. In most cases, prostate cancer has an indolent course however approximately 30,000 still die from the disease every year. Indeed, a subset of men will present with potentially lethal high-risk prostate cancer at diagnosis. We believe that this proportion will increase as fewer men are screened for prostate cancer, amidst ongoing concerns about overdiagnosis and overtreatment.
